Description

Thiafeline 5 mg Film-coated Tablets for Cats

Thiafeline may only be supplied with a valid veterinary prescription issued by your vet. You should only purchase Thiafeline if you have or are in the process of arranging such a prescription. See information bar for further details.

5mg Thiafeline for Cats is a specially formulated medication designed to manage and alleviate the symptoms of hyperthyroidism in cats. It contains the active ingredient thiamazole, which works by inhibiting the production of thyroid hormones, thereby restoring the hormonal balance in your cat’s body. Each tablet is crafted with precision to ensure the right dosage, offering a lifeline for cats suffering from this condition.

Thiafeline Tablets contain 5mg Thiamazole. Thiafeline is used for the stabilisation of hyperthyroidism in cats prior to surgical thyroidectomy. Thiafeline is also used for the long-term treatment of feline hyperthyroidism.

Within a short period of administration, many cat owners notice a significant improvement in their cat’s condition. The excessive thirst, increased urination, and hyperactivity often associated with hyperthyroidism begin to subside, and the cat starts to regain its normal behaviour and energy levels.

The administration of Thiafeline 5mg for Cats is straightforward. The small, easy-to-administer tablets can be given directly or mixed with food, ensuring minimal stress for both the pet and the owner. The dosage can be tailored according to the severity of the condition and the cat’s weight, offering flexibility and ensuring that each cat receives the optimal amount of medication for their individual needs.

Do not use Thiafeline in cats suffering from systemic disease such as primary liver disease or diabetes mellitus. Do not use Thiafeline in cats showing signs of autoimmune disease. Do not use Thiafeline in cats with disorders of white blood cells, such as neutropenia and lymphopenia. Do not use Thiafeline in cats with platelet disorders and coagulopathies (particularly thrombocytopenia). Do not use in pregnant or lactating females. Refer to section 4.7. Do not use in cases of hypersensitivity to thiamazole or to any of the excipients. Special warnings for each target species None. Special precautions for use Special precautions for use in animals As thiamazole can cause haemoconcentration, cats should always have access to drinking water. If more than 10 mg per day is required animals should be monitored particularly carefully.

Use of Thiafeline in cats with renal dysfunction should be subject to careful risk : benefit assessment by the clinician. Due to the effect Thiafeline can have on reducing the glomerular filtration rate, the effect of therapy on renal function should be monitored closely as deterioration of an underlying condition may occur. Haematology must be monitored due to risk of leucopenia or haemolytic anaemia. Any animal that suddenly appears unwell during therapy, particularly if they are febrile, should have a blood sample taken for routine haematology and biochemistry. Neutropenic animals (neutrophil counts 75 %. However, there is a considerable variation between animals. Peak plasma levels occur approximately 0.5-1 hour after dosing (tmax = 0.69 h). Cmax is between 1.1 and 2.7 µg/ml (1.78 µg/ml) and half-life is 3.3 h. Distribution From man and rats it is known that Thiafeline can cross the placenta and concentrates in the foetal thyroid gland. There is also a high rate of transfer into breast milk. The drug residence time in the thyroid gland is assumed to be longer than in the plasma. Metabolism and elimination The metabolism of Thiafeline in cats has not been investigated, however, in rats thiamazole is rapidly metabolised in the thyroid gland. About 64 % of the administered dose being eliminated in the urine and only 7.8 % excreted in faeces. This is in contrast with man where the liver is important for the metabolic degradation of the compound. Pharmaceutical particulars List of excipients Thiafeline 2.5 mg Film-coated Tablets for Cats :- Tablet core: Lactose monohydrate Povidone Sodium starch glycolate Type A Silica, colloidal anhydrous Magnesium stearate Coating: Hypromellose Cellulose, microcrystalline Lactose monohydrate Macrogol Titanium dioxide (E171) Carmoisine (E122) Thiafeline 5 mg Film-coated Tablets for Cats :- Tablet core: Lactose monohydrate Povidone Sodium starch glycolate Type A Silica, colloidal anhydrous Magnesium stearate Coating: Hypromellose Cellulose, microcrystalline Lactose monohydrate Macrogol Titanium dioxide (E171) Sunset Yellow FCF (E110) Quinoline Yellow WS (E104) Major incompatibilities Not applicable. Shelf life Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

Special precautions for storage Keep the blister in the outer package in order to protect from light. Nature and composition of immediate packaging 30 tablets in a cardboard carton containing 1 aluminium/pvcstrips each strip with 30 tablets. 60 tablets in a cardboard carton containing 2 aluminium/pvc strips each strip with 30 tablets. 120 tablets in a cardboard carton containing 4 aluminium/pvc strips each strip with 30 tablets. 150 tablets in a cardboard carton containing 5 aluminium/pvc strips each strip with 30 tablets. 300 tablets in a cardboard carton containing 10 aluminium/pvc strips each strip with 30 tablets. Not all pack sizes may be marketed. Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. Marketing Authorisation Holder (if different from distributor) Le Vet Beheer B.V. Wilgenweg 7 3421 TV Oudewater The Netherlands Marketing Authorisation Number Thiafeline 2.5mg Film-coated Tablets for Cats Vm 41821/4005 Thiafeline 5mg Film-coated Tablets for Cats Vm 41821/4006

Legal category

Thiafeline is a POM-V (Pet Prescription is Required)